MONTREAL, Feb. 27, 2026 /CNW/ - Pendopharm, a division of Pharmascience Inc. (Pendopharm), is pleased to announce that Buccolam® is now available in Canada. The launch of Buccolam® represents an ...

MONTREAL, Aug. 4, 2025 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm Group (Neuraxpharm), a ...

EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for ...

U.K.-based SCM Pharma last year crowed about getting approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for a new sterile manufacturing facility in Newburn in Northumberland ...

Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam® (midazolam oromucosal solution), a newly approved rescue medication ...

"Buccolam, as a licensed preparation of buccal midazolam for emergency treatment of prolonged seizures, is a welcome additional option for care of children with epilepsy," commented Dr Bryan Lynch, ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the CNS, announces the acquisition of the prescription brand Buccolam (oromucosal midazolam) from Takeda ...

ViroPharma Inc. launched its epilepsy drug Buccolam this week in the United Kingdom. ViroPharma Inc. launched its epilepsy drug Buccolam this week in the United Kingdom. The Exton, Pa., ...

The MarketWatch News Department was not involved in the creation of this content. MONTREAL, Aug. 4, 2025 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has ...

Traitement des crises convulsives aiguës prolongées chez les nourrissons (dès 3 mois), jeunes enfants, enfants, adolescents et adultes. BUCCOLAM ne doit être utilisé par les parents/accompagnants que ...